Bristol-Myers Squibb Company Company Profile (NYSE:BMY)

Bristol-Myers Squibb Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Bristol-Myers Squibb Company declared a quarterly dividend on Tuesday, June 13th. Stockholders of record on Friday, July 7th will be given a dividend of $0.39 per share on Tuesday, August 1st. This represents a $1.56 annualized dividend and a dividend yield of 2.70%. The ex-dividend date is Wednesday, July 5th. View Bristol-Myers Squibb Company's Dividend History.

Bristol-Myers Squibb Company (NYSE:BMY) posted its earnings results on Thursday, July, 27th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.73 by $0.01. The company earned $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb Company had a return on equity of 32.33% and a net margin of 22.66%. The firm's quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.69 earnings per share. View Bristol-Myers Squibb Company's Earnings History.

Bristol-Myers Squibb Company is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Bristol-Myers Squibb Company.

Bristol-Myers Squibb Company issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.94.

19 analysts have issued 12-month target prices for Bristol-Myers Squibb Company's shares. Their predictions range from $47.00 to $75.00. On average, they anticipate Bristol-Myers Squibb Company's share price to reach $61.50 in the next year. View Analyst Ratings for Bristol-Myers Squibb Company.

Here are some recent quotes from research analysts about Bristol-Myers Squibb Company stock:

• 1. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
• 2. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
• 3. According to Zacks Investment Research, "Bristol-Myers key products – Opdivo, Orencia, Eliquis and Sprycel – should continue to fuel top-line growth of the company. The company raised its 2016 earnings guidance buoyed by strong trends across the business and posted an encouraging 2017 earnings outlook. Meanwhile, Bristol-Myers’ efforts to develop its pipeline are impressive. However, shares are under pressure with investors expressing disappointment over the company’s failed efforts to expand its key product Opdivo’s label to include the first-line treatment of lung cancer, which could give an edge to its competitors. The company announced that it will not seek an accelerated approval in the U.S. for Opdivo plus Yervoy, for first-line lung cancer. Shares of the company have underperformed that of the industry in the last one year. Moreover, estimates have come down ahead of the fourth-quarter results." (1/24/2017)
• 4. BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)

Bristol-Myers Squibb Company saw a decline in short interest during the month of June. As of June 30th, there was short interest totalling 8,377,031 shares, a decline of 37.9% from the June 15th total of 13,494,570 shares. Based on an average daily trading volume, of 8,181,199 shares, the short-interest ratio is presently 1.0 days. Currently, 0.5% of the shares of the stock are sold short.

Some companies that are related to Bristol-Myers Squibb Company include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Akorn (AKRX) and Taro Pharmaceutical Industries (TARO).

Bristol-Myers Squibb Company's management team includes the folowing people:

• Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer
• Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations
• Louis S. Schmukler, President - Global Manufacturing and Supply
• Ann Powell Judge, Chief Human Resource Officer, Senior Vice President
• Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer
• Sandra Leung, Executive Vice President, General Counsel
• Murdo Gordon, Executive Vice President, Chief Commercial Officer
• Paul von Autenried, Senior Vice President, Chief Information Officer
• Anne Nielsen, Senior Vice President, Chief Compliance and Ethics Officer
• Joseph C. Caldarella, Senior Vice President, Corporate Controller

Bristol-Myers Squibb Company's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.24%), BlackRock Inc. (6.06%), State Street Corp (4.13%), FMR LLC (2.23%), Capital World Investors (1.93%) and Dodge & Cox (1.80%). Company insiders that own Bristol-Myers Squibb Company stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb Company.

Bristol-Myers Squibb Company's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Capital World Investors, Bank of Montreal Can, Thrivent Financial For Lutherans, Bessemer Group Inc., TIAA CREF Investment Management LLC, William Blair Investment Management LLC and Manning & Napier Advisors LLC. Company insiders that have sold Bristol-Myers Squibb Company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler and Sandra Leung. View Insider Buying and Selling for Bristol-Myers Squibb Company.

Bristol-Myers Squibb Company's stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Franklin Resources Inc., Janus Henderson Group PLC, Arrowstreet Capital Limited Partnership, BlackRock Inc., Jennison Associates LLC, Harbour Capital Advisors LLC and Canada Pension Plan Investment Board. View Insider Buying and Selling for Bristol-Myers Squibb Company.

Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $57.87.